In fact, median progression-free survival (PFS) decreased from 20.2 months with rucaparib (Rubraca) monotherapy to 15.0 months with the addition of nivolumab (Opdivo), translating into a hazard ratio ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

Some PARP inhibitors include olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula). At the recent 8th Annual School of Nursing Oncology, Lai presented on the optimized use of PARP ...

This content was published on Sep 18, 2024 The ailing solar company Meyer Burger is attempting to break free with a new restructuring program. The CEO is leaving the company. Numerous employees ...